Analyst Conference Summaries

Biotechnology Investor Aids

Ionis Pharmaceuticals

conference date: February 27, 2019 @ 8:30 AM Pacific Time

Ionis Hits Huntington's Milestone [February 1, 2019 @ Seeking Alpha]

Ionis Rising on RNA Therapy Optimism [December 14, 2018 @ Seeking Alpha]

Akcea Undervalued as Commercial Launches Near [April 12, 2018 @ Seeking Alpha]

Ionis is a Buy on RNA Platform Pipeline [March 7, 2018 @ Seeking Alpha]

Q4 2018
May 4, 2018
August 7, 2018
Nov. 6, 2018
Feb. 27, 2019
Q1 not available
August 8, 2017
Nov. 7, 2017
Feb. 28, 2018

Ionis Pharmaceuticals (IONS) is a biotechnology company specializing in RNA antisense based therapies, including Spinraza. Akcea Therapeutics (AKCA) is majority-owned by Ionis.

Ionis Pharmaceuticals web site

Ionis Pharmaceuticals investor relations



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers